In order to better facilitate the identification of muscle-invasive bladder cancer patients with favourable outcomes to treatment with FGFR inhibitors, Loeffler et al. showed that FGFR3 mutation status could be accurately predicted from H&E slides [38]. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.